Your browser doesn't support javascript.
loading
Drug Resistance to AIDS; Tuberculosis and Malaria in the African Region
Bakyaita, N; Chatora, R; Fall, I. S; Keita, B; Ki-Zerbo, G. A; Kibuga, D; Pana, A; Vaz, R. G.
  • Bakyaita, N; s.af
  • Chatora, R; s.af
  • Fall, I. S; s.af
  • Keita, B; s.af
  • Ki-Zerbo, G. A; s.af
  • Kibuga, D; s.af
  • Pana, A; s.af
  • Vaz, R. G; s.af
Article in English | AIM | ID: biblio-1256237
ABSTRACT
With just 10of the world population; sub-Saharan Africa has the highest burden of HIV/AIDS; tuberculosis and malaria in the world. Both access to and adequate utilization of eff ective treatment with quality-assured medicines are crucial for reducing the disease burden. However; eff orts to improve access to treatment are hampered by the development of HIV; TB and malaria drug resistance. This is a result of genetic mutations and is a major threat to control of HIV/AIDS; TB and malaria. HIV drug resistance can be minimized by good antiretroviral treatment (ART) programmes; removal of barriers to continuous access to ART and reduction of HIVtransmission. Recent surveys conducted at antenatal clinics in several countries in the African Region estimated that HIV resistance to all drug classes is less than 5. A global HIV drug resistance network established in 2001 supports countries in capacity building and guidance on standard procedures for monitoring HIV drug resistance. Multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB) are principally a result of inadequate or poorly administered treatment regimens. The new WHO Stop TB Strategy launched in 2006 identifies management of MDR-TB as a core component of TB control. The magnitude of MDR-TB in the African Region is still unknown. In 2007; 27 countries notifi ed MDR-TB cases; and six reported at least one case of XDR-TB. Following widespread resistance to chloroquine and sulphadoxine-pyrimethamine all malaria-endemic countries except two in the Region have changed the treatment policy to artemisinin-based combination therapy (ACT). The main method of monitoring antimalarial drug resistance is through therapeutic efficacy testing. Todate there has been no confi rmed resistance to ACTs in the African Region. Given the emergence and spread of resistance to HIV; TB and malaria drugs; the purpose of this paper is to describe the issues and challenges and propose a way forward with regard to the prevention and control of such resistance
Subject(s)
Full text: Available Index: AIM (Africa) Main subject: Antiviral Agents / Tuberculosis / Drug Resistance / Delivery of Health Care / Antimalarials Type of study: Practice guideline Language: English Journal: Afr. health monit. (Online) Year: 2003 Type: Article

Similar

MEDLINE

...
LILACS

LIS

Full text: Available Index: AIM (Africa) Main subject: Antiviral Agents / Tuberculosis / Drug Resistance / Delivery of Health Care / Antimalarials Type of study: Practice guideline Language: English Journal: Afr. health monit. (Online) Year: 2003 Type: Article